Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Toulouse – page 80

1 504 clinical trials in Toulouse, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Toulouse at a glance
1 504
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 504 trials in Toulouse

Open in trial search

Atrial fibrillation+1

Not recruiting

Study on Monitoring Anticoagulant Therapy with Rivaroxaban and Warfarin in Patients with Acute Coronary Syndrome and Atrial Fibrillation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Centre Hospitalier De Pau

Cluster headache

Not recruiting

Study on Ketamine and Magnesium Sulfate for Treating Chronic Cluster Headache in Patients Unresponsive to Standard Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:University Hospital Of Clermont-Ferrand

Asthma

Not recruiting

Study on Omalizumab and Mepolizumab for Patients with Severe Allergic and Eosinophilic Asthma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mepolizumab
  • Sponsor:Cliniques Universitaires Saint-Luc

Immune thrombocytopenia

Not recruiting

Study of rituximab and belimumab combination compared to rituximab alone in adults with persistent or chronic immune thrombocytopenia (ITP)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute myeloid leukaemia

Not recruiting

Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:The University Of Birmingham

Non-small cell lung cancer stage IV

Not recruiting

Study of Atezolizumab, Carboplatin, and Paclitaxel for Elderly Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Ovarian cancer recurrent

Not recruiting

Study of Azenosertib and Niraparib for Patients with Platinum-Resistant Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Cryoglobulinaemia

Not recruiting

Study of Isatuximab for Patients with Type I Cryoglobulinemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Daratumumab, and Dexamethasone for Frail Patients with Untreated Multiple Myeloma Not Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Gastrointestinal carcinoma

Not recruiting

Study on the Safety and Effectiveness of Domvanalimab, Zimberelimab, and Quemliclustat in Adults with Advanced Upper Gastrointestinal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Arcus Biosciences Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Kite Pharma Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Toulouse

What the registry says about research in the country

01 Cardiovascular and Metabolic Research

Innovative studies focusing on heart disease treatment, including trials for TTR amyloidosis and prevention of heart failure. Advanced therapeutic approaches using novel compounds like baxdrostat in combination with established medications.

  • TTR Amyloidosis Cardiomyopathy
  • Heart Failure Prevention
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive cancer research targeting multiple types of malignancies, including head and neck cancer, gastric cancer, and advanced pancreatic cancer. Novel approaches using targeted therapies and immunotherapy combinations.

  • Head & Neck Squamous Cell Carcinoma
  • Gastric and GEJ Cancer
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
03 Neurological Disorders

Advanced research in neurodegenerative conditions and movement disorders, including studies on frontotemporal dementia, essential tremor, and traumatic brain injury outcomes.

  • Frontotemporal Dementia
  • Essential Tremor
  • Traumatic Brain Injury
  • Multiple Sclerosis
04 Autoimmune and Inflammatory Conditions

Studies investigating new treatments for inflammatory diseases, including innovative approaches for Crohn's disease, psoriatic arthritis, and myasthenia gravis.

  • Crohn's Disease
  • Psoriatic Arthritis
  • Myasthenia Gravis
  • Idiopathic Pulmonary Fibrosis
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.